9 found
Order:
Disambiguations
Alison Bateman-House [6]Alison S. Bateman-House [3]
  1.  47
    Moral Issues of Human-Non-Human Primate Neural Grafting.Mark Greene, Kathryn Schill, Shoji Takahashi, Alison Bateman-House, Tom Beauchamp, Hilary Bok, Dorothy Cheney, Joseph Coyle, Terrence Deacon, Daniel Dennett, Peter Donovan, Owen Flanagan, Steven Goldman, Henry Greely, Lee Martin & Earl Miller - 2005 - Science 309 (5733):385-386.
    The scientific, ethical, and policy issues raised by research involving the engraftment of human neural stem cells into the brains of nonhuman primates are explored by an interdisciplinary working group in this Policy Forum. The authors consider the possibility that this research might alter the cognitive capacities of recipient great apes and monkeys, with potential significance for their moral status.
    Direct download  
    Translate
     
     
    Export citation  
     
    Bookmark   25 citations  
  2.  69
    Public Stem Cell Banks: Considerations of Justice in Stem Cell Research and Therapy.Ruth R. Faden, Liza Dawson, Alison S. Bateman-House, Dawn Mueller Agnew, Hilary Bok, Dan W. Brock, Aravinda Chakravarti, Xiao-Jiang Gao, Mark Greene, John A. Hansen, Patricia A. King, Stephen J. O'Brien, David H. Sachs, Kathryn E. Schill, Andrew Siegel, Davor Solter, Sonia M. Suter, Catherine M. Verfaillie, LeRoy B. Walters & John D. Gearhart - 2003 - Hastings Center Report 33 (6):13-27.
    If stem cell-based therapies are developed, we will likely confront a difficult problem of justice: for biological reasons alone, the new therapies might benefit only a limited range of patients. In fact, they might benefit primarily white Americans, thereby exacerbating long-standing differences in health and health care.
    Direct download (5 more)  
     
    Export citation  
     
    Bookmark   9 citations  
  3.  19
    Fair, Just and Compassionate: A Pilot for Making Allocation Decisions for Patients Requesting Experimental Drugs Outside of Clinical Trials.Arthur L. Caplan, J. Russell Teagarden, Lisa Kearns, Alison S. Bateman-House, Edith Mitchell, Thalia Arawi, Ross Upshur, Ilina Singh, Joanna Rozynska, Valerie Cwik & Sharon L. Gardner - 2018 - Journal of Medical Ethics 44 (11):761-767.
    Patients have received experimental pharmaceuticals outside of clinical trials for decades. There are no industry-wide best practices, and many companies that have granted compassionate use, or ‘preapproval’, access to their investigational products have done so without fanfare and without divulging the process or grounds on which decisions were made. The number of compassionate use requests has increased over time. Driving the demand are new treatments for serious unmet medical needs; patient advocacy groups pressing for access to emerging treatments; internet platforms (...)
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  4.  20
    Preapproval Nontrial Access and Off-Label Use: Do They Meet Criteria for Dual-Deviation Review?Carolyn Riley Chapman, Kelly McBride Folkers, Andrew McFadyen, Lesha D. Shah & Alison Bateman-House - 2019 - American Journal of Bioethics 19 (6):22-25.
    Volume 19, Issue 6, June 2019, Page 22-25.
    Direct download (4 more)  
     
    Export citation  
     
    Bookmark  
  5.  26
    Safety Issues In Cell-Based Intervention Trials.Liza Dawson, Alison S. Bateman-House, Dawn Mueller Agnew, Hilary Bok, Dan W. Brock, Aravinda Chakravarti, Mark Greene, Patricia King, Stephen J. O'Brien, David H. Sachs, Kathryn E. Schill, Andrew Siegel & Davor Solter - 2003 - Fertility and Sterility 80 (5):1077-1085.
    We report on the deliberations of an interdisciplinary group of experts in science, law, and philosophy who convened to discuss novel ethical and policy challenges in stem cell research. In this report we discuss the ethical and policy implications of safety concerns in the transition from basic laboratory research to clinical applications of cell-based therapies derived from stem cells. Although many features of this transition from lab to clinic are common to other therapies, three aspects of stem cell biology pose (...)
    Direct download  
    Translate
     
     
    Export citation  
     
    Bookmark   4 citations  
  6.  14
    Compassion for Each Individual's Own Sake.Arthur Caplan & Alison Bateman-House - 2014 - American Journal of Bioethics 14 (11):16-17.
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  7.  12
    Single-Patient Expanded Access Requests: IRB Professionals’ Experiences and Perspectives.Carolyn Riley Chapman, Jenni A. Shearston, Kelly McBride Folkers, Barbara K. Redman, Arthur Caplan & Alison Bateman-House - 2019 - Ajob Empirical Bioethics 10 (2):88-99.
    No categories
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  8.  6
    Putting Local All-Ages Bicycle Helmet Ordinances in Context.Alison Bateman-House & Kathleen Bachynski - 2019 - Journal of Law, Medicine and Ethics 47 (2):291-293.
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  9.  34
    Free to Consume? Anti-Paternalism and the Politics of New York City’s Soda Cap Saga.Alison Bateman-House, Ronald Bayer, James Colgrove, Amy L. Fairchild & Caitlin E. McMahon - 2018 - Public Health Ethics 11 (1).
    In 2012, New York City Mayor Michael Bloomberg proposed capping the size of sugary beverages that could be sold in the city’s restaurants, sporting and entertainment facilities and food carts. After a lawsuit and multiple appeals, the proposal died in June 2014, deemed an unconstitutional overreach. In dissecting the saga of the proposed soda cap, we highlight both the political perils of certain anti-obesity efforts and, more broadly, the challenges to public health when issues of consumer choice and the threat (...)
    Direct download (4 more)  
     
    Export citation  
     
    Bookmark